cx-f-roger-greenhalgh

Roger Greenhalgh.

Fifteen-year follow-up of the Endovascular Aneurysm Repair (EVAR) 1 Trial will be presented for the first time at CX 2016. The EVAR 1 Trial was the first EVAR vs. open repair abdominal aortic aneurysm trial to be conducted and is the first to reach 15 years of follow-up.

“This is certainly one of the key topics to be presented at the CX Abdominal Aortic Aneurysm Challenges Day (Wednesday, 27 April) of CX 2016,” says Roger Greenhalgh, chairman of the CX Programme Organising Board.

The last EVAR 1 Trial follow-up—the 10-year follow-up—presented at CX 2010 and published in The New England Journal of Medicine, demonstrated no significant differences between endovascular aneurysm repair and open repair in terms of mortality. “This extra follow-up has been performed in order to see what happened to that result out to 15 years. It is very important to know how the methods have done in the long term,” notes Greenhalgh.

The CX Abdominal Aortic Aneurysm Challenges Day will take place at the Charing Cross Symposium on Wednesday 27 April – Upper Main Auditorium, Olympia Grand, London, UK

Click here to see the CX Interactive Main Programme – Abdominal Aortic Aneurysm Challenges

Click here to register